References
- Arad G, Levy R, Hillman D, Kaempfer R: Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation.
Nat Med 2000, 6:414-421. PubMed Abstract | Publisher Full Text 
- Eriksson BK, Andersson J, Holm SE, Norgren M: Invasive group A streptococcal infections: T1M1 isolates expressing pyrogenic exotoxins A and B in combination with selective lack of toxin-neutralizing antibodies are associated with increased risk of streptococcal toxic shock syndrome.
J Infect Dis 1999, 180:410-418. PubMed Abstract | Publisher Full Text 
- Sriskandan S, Unnikrishnan M, Krausz T, Cohen J: Molecular analysis of the role of streptococcal pyrogenic exotoxin A (SPEA) in invasive soft tissue infection resulting from Streptococcus pyogenes.
Mol Microbiol 1999, 33:778-790. PubMed Abstract | Publisher Full Text 
- Visvanathan K, Charles A, Bannan J, Pugach P, Kashfi K, Zabriskie JB: Inhibition of bacterial superantigens by peptides and antibodies.
Infect Immun 2001, 69:875-884. PubMed Abstract | Publisher Full Text | PubMed Central Full Text 
- Sriskandan S, McKee A, Hall L, Cohen J: Comparative effects of clindamycin and ampicillin on superantigenic activity of streptococcus pyogenes.
J Antimicrob Chemother 1997, 40:275-277. PubMed Abstract | Publisher Full Text 
- Zimbelman J, Palmer A, Todd J: Improved outcome of clindamycin compared with beta-lactam antibiotic treatment for invasive streptococcus pyogenes infection.
Pediatr Infect Dis J 1999, 18:1096-1100. PubMed Abstract | Publisher Full Text 
- Norrby-Teglund A, Kaul R, Low DE, McGeer A, Newton DW, Andersson J, Andersson U, Kotb M: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigen-induced T cell proliferation and cytokine production.
J Immunol 1996, 156:3057-3064. PubMed Abstract 
- Norrby-Teglund A, Ihendyane N, Kansal R, Basma H, Kotb M, Andersson J, Hammarstrom L: Relative neutralizing activity in polyspecific IgM, IgA, and IgG preparations against group A streptococcal superantigens.
Clin Infect Dis 2000, 31:1175-1182. PubMed Abstract | Publisher Full Text 
- Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group.
Clin Infect Dis 1999, 28:800-807. PubMed Abstract 
- Roggiani M, Stoehr JA, Olmsted SB, Matsuka YV, Pillai S, Ohlendorf DH, Schlievert PM: Toxoids of streptococcal pyrogenic exotoxin A are protective in rabbit models of streptococcal toxic shock syndrome.
InfectImmun 2000, 68:5011-5017. Publisher Full Text 
- McCormick JK, Tripp TJ, Olmsted SB, Matsuka YV, Gahr PJ, Ohlendorf DH, Schlievert PM: Development of streptococcal pyrogenic exotoxin C vaccine toxoids that are protective in the rabbit model of toxic shock syndrome.
J Immunol 2000, 165:2306-2312. PubMed Abstract | Publisher Full Text 
|